Product Code: A12303
The global opioid use disorder market was valued at $196.2 million in 2021, and is projected to reach $385.8 million by 2031, registering a CAGR of 7.1% from 2022 to 2031. Opioid is a class of pain relievers that includes substances, which relax muscles and alleviate pain & stress. Prescription opioids are used to treat moderate-to-severe pain such as hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids. Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects. Opioids use disorder is regarded as brain disorder because it involves functional alterations to brain circuits involved in motivation, stress, self-control, and decision-making, and those changes may persist for a long period after drug use has stopped. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
The opioids use disorder market is driven by increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions. For instance, according to World Cancer Research Fund International, in 2020, around 18,094,716 new cancer cases diagnosed over the globe. As per the same source Breast and lung cancers were the most common cancers worldwide, 2,261,419 breast cancer and 2,206,771 lung cancer new cases diagnosed over the globe. Thus, rise in number of cancer cases cause increase in incidence of surgeries. Surge in number of surgical procedures cause rise in use of opioid drugs to relieve post-surgical pain. Therefore, this factor can cause addiction of opioid drugs in patients. Thus, this factor is anticipated to drive the growth of opioids use disorder market. Moreover, according to the Journal of JAMA Netw Open, in December 2021, around 5. 9 million population were reported to have undergone surgical procedure in the Rest of LAMEA In addition, according to Canadian Joint Replacement Registry (CJRR), approximately more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in the Canada from 2019 to 2020. As per the same source the knee and hip replacement surgery is the second most common surgery in Canada. This report also states 2.4% increase in the hip replacement surgery from 2019 to 2020.
In addition, increase in consideration of buprenorphine patches as an effective treatment mode to propel opioids use disorder market growth. The increase in use of buprenorphine patches as a successful treatment for opioid use disorder is one of the anticipated trends in the global market for treating opioid addiction. The use of buprenorphine patches is regarded as a cutting-edge strategy for treating opioid use disorder. Transdermal patches are a more pleasant drug delivery method that successfully lowers pain and can be self-administered by the patient than conventional therapy modalities such as injections. These buprenorphine patches can also serve as a potential substitute for people who need immediate treatment for opioid use disorder. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2020 to 2019, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019.
Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment and medicine used at public health centers, such as hospitals. Hence, the rise in healthcare expenditure across the globe is expected to fuel the demand for opioids use disorder drugs application for treatment purpose, thereby boosting the growth of opioid use disorder market. On the other hand, side effects associated to opioids use disorder drugs are anticipated to restrain the growth of the opioids use disorder market.
The opioids use disorder market is segmented on the basis of type, age group, route of administration, distribution channel, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. On the basis of route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global opioids use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.,
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Agonist
- Type
- Methadone
- Buprenorphine
- Antagonist
By Age group
- 19 to 39
- 40 to 59
- Age 60 and over
By Route of Administration
- Oral
- Intravenous
- Sublingual
By Distribution channal
- Hospital pharmacy
- Retail Pharmacy
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Alkermes, Inc.
- AstraZeneca plc
- BioDelivery Sciences International Inc.,
- braeburn pharmaceuticals
- Camurus
- Dr Reddy Laboratories Ltd
- Pear Therapeutics
- Hikma Pharmaceuticals PLC,
- mallinckrodt pharmaceuticals
- NYC Health Hospitals
- Orexo AB
- OREXO AB
- Indivior PLC
- Reckitt Benckiser Pharmaceuticals Inc
- Sandoz
- Titan Pharmaceuticals, Inc.
- Viatris Inc
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: OPIOID USE DISORDER MARKET, BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Agonist
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Agonist Opioid Use Disorder Market by Type
- 4.2.4.1 Methadone Market size and forecast, by region
- 4.2.4.2 Buprenorphine Market size and forecast, by region
- 4.3 Antagonist
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
CHAPTER 5: OPIOID USE DISORDER MARKET, BY AGE GROUP
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 19 to 39
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 40 to 59
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Age 60 and over
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
CHAPTER 6: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Oral
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Intravenous
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Sublingual
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
CHAPTER 7: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Hospital pharmacy
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Retail Pharmacy
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
CHAPTER 8: OPIOID USE DISORDER MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Drug Type
- 8.2.2.1 North America Agonist Opioid Use Disorder Market by Type
- 8.2.3 North America Market size and forecast, by Age group
- 8.2.4 North America Market size and forecast, by Route of Administration
- 8.2.5 North America Market size and forecast, by Distribution channal
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by Drug Type
- 8.2.6.1.2 Market size and forecast, by Age group
- 8.2.6.1.3 Market size and forecast, by Route of Administration
- 8.2.6.1.4 Market size and forecast, by Distribution channal
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by Drug Type
- 8.2.6.2.2 Market size and forecast, by Age group
- 8.2.6.2.3 Market size and forecast, by Route of Administration
- 8.2.6.2.4 Market size and forecast, by Distribution channal
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by Drug Type
- 8.2.6.3.2 Market size and forecast, by Age group
- 8.2.6.3.3 Market size and forecast, by Route of Administration
- 8.2.6.3.4 Market size and forecast, by Distribution channal
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Drug Type
- 8.3.2.1 Europe Agonist Opioid Use Disorder Market by Type
- 8.3.3 Europe Market size and forecast, by Age group
- 8.3.4 Europe Market size and forecast, by Route of Administration
- 8.3.5 Europe Market size and forecast, by Distribution channal
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by Drug Type
- 8.3.6.1.2 Market size and forecast, by Age group
- 8.3.6.1.3 Market size and forecast, by Route of Administration
- 8.3.6.1.4 Market size and forecast, by Distribution channal
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by Drug Type
- 8.3.6.2.2 Market size and forecast, by Age group
- 8.3.6.2.3 Market size and forecast, by Route of Administration
- 8.3.6.2.4 Market size and forecast, by Distribution channal
- 8.3.6.3 UK
- 8.3.6.3.1 Market size and forecast, by Drug Type
- 8.3.6.3.2 Market size and forecast, by Age group
- 8.3.6.3.3 Market size and forecast, by Route of Administration
- 8.3.6.3.4 Market size and forecast, by Distribution channal
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by Drug Type
- 8.3.6.4.2 Market size and forecast, by Age group
- 8.3.6.4.3 Market size and forecast, by Route of Administration
- 8.3.6.4.4 Market size and forecast, by Distribution channal
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by Drug Type
- 8.3.6.5.2 Market size and forecast, by Age group
- 8.3.6.5.3 Market size and forecast, by Route of Administration
- 8.3.6.5.4 Market size and forecast, by Distribution channal
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by Drug Type
- 8.3.6.6.2 Market size and forecast, by Age group
- 8.3.6.6.3 Market size and forecast, by Route of Administration
- 8.3.6.6.4 Market size and forecast, by Distribution channal
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Drug Type
- 8.4.2.1 Asia-Pacific Agonist Opioid Use Disorder Market by Type
- 8.4.3 Asia-Pacific Market size and forecast, by Age group
- 8.4.4 Asia-Pacific Market size and forecast, by Route of Administration
- 8.4.5 Asia-Pacific Market size and forecast, by Distribution channal
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 China
- 8.4.6.1.1 Market size and forecast, by Drug Type
- 8.4.6.1.2 Market size and forecast, by Age group
- 8.4.6.1.3 Market size and forecast, by Route of Administration
- 8.4.6.1.4 Market size and forecast, by Distribution channal
- 8.4.6.2 Japan
- 8.4.6.2.1 Market size and forecast, by Drug Type
- 8.4.6.2.2 Market size and forecast, by Age group
- 8.4.6.2.3 Market size and forecast, by Route of Administration
- 8.4.6.2.4 Market size and forecast, by Distribution channal
- 8.4.6.3 India
- 8.4.6.3.1 Market size and forecast, by Drug Type
- 8.4.6.3.2 Market size and forecast, by Age group
- 8.4.6.3.3 Market size and forecast, by Route of Administration
- 8.4.6.3.4 Market size and forecast, by Distribution channal
- 8.4.6.4 Australia
- 8.4.6.4.1 Market size and forecast, by Drug Type
- 8.4.6.4.2 Market size and forecast, by Age group
- 8.4.6.4.3 Market size and forecast, by Route of Administration
- 8.4.6.4.4 Market size and forecast, by Distribution channal
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by Drug Type
- 8.4.6.5.2 Market size and forecast, by Age group
- 8.4.6.5.3 Market size and forecast, by Route of Administration
- 8.4.6.5.4 Market size and forecast, by Distribution channal
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by Drug Type
- 8.4.6.6.2 Market size and forecast, by Age group
- 8.4.6.6.3 Market size and forecast, by Route of Administration
- 8.4.6.6.4 Market size and forecast, by Distribution channal
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Drug Type
- 8.5.2.1 LAMEA Agonist Opioid Use Disorder Market by Type
- 8.5.3 LAMEA Market size and forecast, by Age group
- 8.5.4 LAMEA Market size and forecast, by Route of Administration
- 8.5.5 LAMEA Market size and forecast, by Distribution channal
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by Drug Type
- 8.5.6.1.2 Market size and forecast, by Age group
- 8.5.6.1.3 Market size and forecast, by Route of Administration
- 8.5.6.1.4 Market size and forecast, by Distribution channal
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by Drug Type
- 8.5.6.2.2 Market size and forecast, by Age group
- 8.5.6.2.3 Market size and forecast, by Route of Administration
- 8.5.6.2.4 Market size and forecast, by Distribution channal
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by Drug Type
- 8.5.6.3.2 Market size and forecast, by Age group
- 8.5.6.3.3 Market size and forecast, by Route of Administration
- 8.5.6.3.4 Market size and forecast, by Distribution channal
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by Drug Type
- 8.5.6.4.2 Market size and forecast, by Age group
- 8.5.6.4.3 Market size and forecast, by Route of Administration
- 8.5.6.4.4 Market size and forecast, by Distribution channal
CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
CHAPTER 10: COMPANY PROFILES
- 10.1 Alkermes, Inc.
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 AstraZeneca plc
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 BioDelivery Sciences International Inc.,
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 braeburn pharmaceuticals
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 Camurus
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Dr Reddy Laboratories Ltd
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 Pear Therapeutics
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Hikma Pharmaceuticals PLC,
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 mallinckrodt pharmaceuticals
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 NYC Health Hospitals
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments
- 10.11 Orexo AB
- 10.11.1 Company overview
- 10.11.2 Company snapshot
- 10.11.3 Operating business segments
- 10.11.4 Product portfolio
- 10.11.5 Business performance
- 10.11.6 Key strategic moves and developments
- 10.12 OREXO AB
- 10.12.1 Company overview
- 10.12.2 Company snapshot
- 10.12.3 Operating business segments
- 10.12.4 Product portfolio
- 10.12.5 Business performance
- 10.12.6 Key strategic moves and developments
- 10.13 Indivior PLC
- 10.13.1 Company overview
- 10.13.2 Company snapshot
- 10.13.3 Operating business segments
- 10.13.4 Product portfolio
- 10.13.5 Business performance
- 10.13.6 Key strategic moves and developments
- 10.14 Reckitt Benckiser Pharmaceuticals Inc
- 10.14.1 Company overview
- 10.14.2 Company snapshot
- 10.14.3 Operating business segments
- 10.14.4 Product portfolio
- 10.14.5 Business performance
- 10.14.6 Key strategic moves and developments
- 10.15 Sandoz
- 10.15.1 Company overview
- 10.15.2 Company snapshot
- 10.15.3 Operating business segments
- 10.15.4 Product portfolio
- 10.15.5 Business performance
- 10.15.6 Key strategic moves and developments
- 10.16 Titan Pharmaceuticals, Inc.
- 10.16.1 Company overview
- 10.16.2 Company snapshot
- 10.16.3 Operating business segments
- 10.16.4 Product portfolio
- 10.16.5 Business performance
- 10.16.6 Key strategic moves and developments
- 10.17 Viatris Inc
- 10.17.1 Company overview
- 10.17.2 Company snapshot
- 10.17.3 Operating business segments
- 10.17.4 Product portfolio
- 10.17.5 Business performance
- 10.17.6 Key strategic moves and developments